Immunovant Sciences Gmbh
Clinical trials sponsored by Immunovant Sciences Gmbh, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could tame lupus skin flares Results expected Oct 2026 (estimated)
- New drug aims to tame overactive thyroid without lifelong pills Results expected May 2027 (estimated)
- New shot could help when arthritis drugs fail Results expected Sep 2027 (estimated)
-
New weekly shot aims to tame Sjögren's Flare-Ups
Disease control OngoingThis study tests an experimental drug called IMVT-1402 in 180 adults with moderate to severe Sjögren's disease. Participants receive either the drug or a placebo as a weekly injection under the skin for 24 weeks. The goal is to see if the drug can reduce overall disease activity …
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New shot could tame lupus skin flares
Disease control OngoingThis study tests an experimental drug called IMVT-1402 in people with lupus-related skin rashes (subacute or chronic cutaneous lupus) that haven't gotten better with standard treatments. About 56 participants will receive either the drug or a placebo for 12 weeks, then all get th…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug aims to tame Graves' disease Long-Term
Disease control By invitation onlyThis study tests a drug called IMVT-1402 in adults with Graves' disease, a condition where the immune system attacks the thyroid. The goal is to see if the drug can help patients stay healthy without needing other treatments. About 372 people who completed earlier studies will ta…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New shot could help when arthritis drugs fail
Disease control OngoingThis study tests a new drug called IMVT-1402 in 120 adults with active, difficult-to-treat rheumatoid arthritis. Participants receive weekly injections of either the drug or a placebo. The goal is to see if the drug helps maintain symptom improvement over 28 weeks.
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC